As previously mentioned, this clinical trial assessed both clinical outcomes and biopsy dystrophin protein levels over a 24-week period and involved six DMD patients (8–17 years of age), who received the drug via IV injection (Table 1). Here, DMD is linked to Duchenne muscular dystrophy.